Who We Are

Our history

More than 20 years of revolutionary therapies

Seattle Genetics initiates operations in Bothell, Washington.

1998

1999

Our research into anti-CD30 antibodies begins.

2001

Our scientists synthesize monomethyl auristatin E (MMAE), the cytotoxic drug payload for our first antibody–drug conjugate (ADC), brentuximab vedotin (ADCETRIS®).

2006

The first patient is treated with ADCETRIS.

2007

Seagen and Agensys (acquired by Astellas) enter into a collaboration, resulting in the co-development of enfortumab vedotin, an ADC that targets Nectin-4.

2009

Seagen and Takeda agree to globally co-develop and commercialize ADCETRIS.

2011

ADCETRIS® (brentuximab vedotin) is approved in the U.S. for relapsed classical Hodgkin lymphoma (cHL) and relapsed systemic anaplastic large cell lymphoma (ALCL).

2012

ADCETRIS is approved in the European Union for certain patients with classical Hodgkin lymphoma (cHL).

2015

Seagen expands access to ADC technology via collaborations with global biotechnology and pharmaceutical industry leaders.

2016

Our European headquarters opens in Zug, Switzerland.

2017

ADCETRIS is approved in the U.S. for primary cutaneous ALCL or CD30-expressing mycosis fungoides, the most common type of cutaneous T-cell lymphoma (CTCL).

2018

20-year anniversary of Seagen.

2018

ADCETRIS is approved in the U.S. in combination with chemotherapy for previously untreated stage 3 or 4 cHL.

ADCETRIS is approved in the U.S. in combination with chemotherapy for previously untreated sALCL or other CD30-expressing peripheral T-cell lymphomas (PTCL).

Seagen acquires Cascadian Therapeutics, including the late-stage investigational agent tucatinib.

2019

PADCEV® (enfortumab vedotin-ejfv) is approved in the U.S. to treat certain types of metastatic urothelial cancers post PD(L)-1 inhibitor and a platinum-containing chemotherapy.

2019

ADCETRIS is established as a foundation of care for certain types of CD30-expressing lymphomas and approved in more than 70 countries.

2020

TUKYSA® (tucatinib) is approved in the U.S. and other countries for certain HER2+ metastatic breast cancers in combination with trastuzumab and capecitabine -- our third approved and first wholly-owned medicine.

2020

Seattle Genetics, Inc. changes its name to Seagen Inc. to reflect the transformation of the company from its strong Seattle roots into a global operation.

Our commitment to innovation and making a meaningful impact in cancer care continues.